MedTrace Logo

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

NCT06182579 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-09-17

No results posted yet for this study

Summary

This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.

Conditions

  • Advanced Solid Tumor
  • Intratumoral Injection

Interventions

DRUG

RiMO-401

• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy

Sponsors & Collaborators

  • Coordination Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-22
Primary Completion
2025-06-16
Completion
2025-06-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06182579 on ClinicalTrials.gov